Premium
Cost‐effectiveness analysis of late prophylaxis vs. on‐demand treatment for severe haemophilia A in Italy
Author(s) -
Coppola A.,
D'Ausilio A.,
Aiello A.,
Amoresano S.,
Toumi M.,
Mathew P.,
Tagliaferri A.
Publication year - 2017
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/hae.13185
Subject(s) - medicine , haemophilia , cost effectiveness , haemophilia a , quality adjusted life year , pediatrics , quality of life (healthcare) , cost effectiveness analysis , risk analysis (engineering) , nursing
Long‐term regular administrations of factor VIII ( FVIII ) concentrate (prophylaxis) initiated at an early age prevents bleeding in patients with severe haemophilia A ( HA ). The 5‐year prospective Italian POTTER study provided evidence of benefits in adolescents and adults of late prophylaxis ( LP ) vs. on‐demand therapy ( OD ) in reducing bleeding episodes and joint morbidity and improving quality of life; however, costs were increased. Aim The aim of this study was to determine the cost‐effectiveness of LP vs. OD with sucrose‐formulated recombinant FVIII in adolescents and adults with severe HA in Italy. Methods A Markov model evaluated lifetime cost‐effectiveness of LP vs. OD in patients with severe HA in Italy, from both the healthcare and societal perspectives. Clinical input parameters were taken from the POTTER study and published literature. Health utility values were assigned to each health state as measured by the joint disease severity Pettersson score. Costs were expressed in Euro (€) 2014, including drug and other medical costs. Sensitivity analyses were performed considering societal perspective (including productivity lost) and varying relative risk of bleeding episodes between regimens. Clinical outcomes and costs were discounted at 6% according to previous studies. Results Lifetime incremental discounted quality‐adjusted life‐years ( QALY s) were +4.26, whereas incremental discounted costs were +€229,694 from a healthcare perspective, with estimated incremental cost‐effectiveness ratios ( ICER s) equal to €53,978/ QALY . Sensitivity analyses confirmed the base‐case results showing lower ICER s with the societal perspective. Conclusion Late prophylaxis vs. on‐demand therapy results in a cost‐effective approach with ICER s falling below the threshold considered acceptable in Italy.